stars 1 stars 2 stars 3

Izon Science enables nanoparticle researchers across a range of disciplines to isolate and characterise particles with precision. With the field of extracellular vesicles (EVs) now pushing towards clinical applications, Izon is meeting the need for scalable EV isolation solutions for EV-based diagnostics and EV-based therapeutics, as well as fundamental EV research. This is achieved through its evolving range of size exclusion chromatography-based qEV columns, associated instrumentation for automating particle isolation, and customised bioprocessing development services. With such diverse customers, the qEV platform accommodates a broad range of sample types and volumes. Meanwhile, Izon brings high-resolution insights to the physical characterisation of EVs, lipid nanoparticles, viruses and beyond, through the Exoid and its Tunable Resistive Pulse Sensing (TRPS) technology. Through its unique particle-by-particle approach, the Exoid allows researchers across fundamental research and nanomedicine development to measure particle size, concentration, and zeta potential. Izon’s network is global, with offices located in Christchurch (New Zealand – Headquarters), Lyon (France), Boston and Texas (US).

Izon Science Questions

The Izon Science annual revenue was $17.8 million in 2026.

Anoop Pal is the Chief Business Officer of Izon Science.

26 people are employed at Izon Science.

Izon Science is based in Christchurch, Canterbury.

The NAICS codes for Izon Science are [33, 334].

The SIC codes for Izon Science are [38, 382].

Top Izon Science Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users